TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06220045

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Polyvinylidene fluoride mesh
Description: Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polyvinylidene fluoride mesh.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prophylactic polypropylene mesh
Description: Midline laparotomy closure using the small bites technique associated with a prophylactic suprafascial polypropylene mesh.
Study: NCT04893421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOLLI Localization
Description: Patients will be implanted with a MOLLI seed using a specialized introducer needle under imaging guidance. A special handhold probe and detection system will be used intraoperatively to assist in excision.
Study: NCT04222660

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackmores Omega Daily (4 1g capsules per day)
Description: Subjects enrolled in phase two of the study will be instructed to take 4 capsules per day (2 in the morning and 2 in the evening). Each capsule contains 1000 mg of triglyceride; 35% eicosapentaenoic acid and 25% docosahexaenoic acid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackmores Omega Daily (4 1g capsules per day)
Description: Subjects enrolled in phase two of the study will be instructed to take 4 capsules per day (2 in the morning and 2 in the evening). Each capsule contains 1000 mg of triglyceride; 35% eicosapentaenoic acid and 25% docosahexaenoic acid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackmores Omega Daily (4 1g capsules per day)
Description: Subjects enrolled in phase two of the study will be instructed to take 4 capsules per day (2 in the morning and 2 in the evening). Each capsule contains 1000 mg of triglyceride; 35% eicosapentaenoic acid and 25% docosahexaenoic acid.
Study: NCT04956354

Intervention type: DEVICE
Intervention: ANNE™ Monitoring System (2 sensors) - version B
Description: ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Chest and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - A chest unit (ANNE™ Chest) with embedded battery, sensors, and a three-axis accelerometer that captures the following signals: electrocardiography (ECG), temperature, seismocardiography (SCG) and the chest wall movements.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals.
Study: NCT04354103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Atomoxetine
Study: NCT04956354

Intervention type: DEVICE
Intervention: ANNE™ Monitoring System (2 sensors) - version C
Description: ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Arc and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - ANNE™ Arc with a Lithium-Polymer battery that contains a 6-axial inertial measurement unit (IMU), which includes a 3-axis gyroscope and 3-axis accelerometer, a power management component, an analog front-end component, passive electrodes for ECG, and bio-impedance feature that capture the following waveforms: heart rate (HR), respiratory rate (RR) and skin temperature.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals.

Intervention type: DEVICE
Intervention: ANNE™ Monitoring System (2 sensors) - version C
Description: ANNE™ is a wireless vital sign monitoring device that uses soft, flexible, skin-mountable biosensors (ANNE™ Arc and ANNE™ Limb) with Bluetooth® 5 enabled and encrypted data communication to an iPad application. Study sensors to be applied on patients are:~Sensor 1 - ANNE™ Arc with a Lithium-Polymer battery that contains a 6-axial inertial measurement unit (IMU), which includes a 3-axis gyroscope and 3-axis accelerometer, a power management component, an analog front-end component, passive electrodes for ECG, and bio-impedance feature that capture the following waveforms: heart rate (HR), respiratory rate (RR) and skin temperature.~Sensor 2 - A limb unit (ANNE™ Limb) with embedded battery that captures the photoplethysmography (PPG) and SpO2 signals.
Study: NCT06224270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Recombinant Zoster Vaccine (RZV)
Description: The RZV vaccine is indicated for prevention of herpes zoster (HZ) in adults aged 18 years and older who are or will be at increased risk of HZ. Patients with IBD on immunosuppressive therapy are at increased risk for HZ.
Study: NCT05851417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast Field-Cycling (FFC) imaging
Description: FFC scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast Field-Cycling (FFC) imaging
Description: FFC scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast Field-Cycling (FFC) imaging
Description: FFC scan
Study: NCT05484024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 inhibitor

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short-course radiotherapy
Description: Pelvic radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Pelvic radiation

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX/mFOLFOX
Description: chemotherapy regimen

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CAPOX/mFOLFOX
Description: chemotherapy regimen
Study: NCT05507203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: Administered once daily in the morning with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: Administered once daily in the morning with food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once daily in the morning with food
Study: NCT06231628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous cementoplasty
Description: Percutaneous image guided cementoplasty will be performed as follows:~Low-viscosity radiopaque bone cement will be quickly mixed and transferred to 1-ml syringes to reduce injection resistance. Injection will be initiated 2-4 min after mixing. When the resistance to cement injection becomes high in the beginning, the cement will be pushed in with a stylet, and it will go well afterward. As much bone cement as possible will be injected while avoiding leakage into the hip joint, sciatic notch, or veins under fluoroscopic monitoring. When significant cement leakage occurred at the initial stage, cement injection will be performed via another route or will be stopped and resumed when the cement viscosity increased. The cement will begin to harden after 8 min, and the operator, therefore, will aim to complete the delivery of the injection within 10 min. The injection needles must be removed before the cement hardens completely
Study: NCT05526911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBAJ-876
Description: * Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~* Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~* Day 20 and Day 21: 200 mg TBAJ-876 oral suspension, fasting~* Day 22 to Day 24: 150 mg TBAJ-876 oral suspension, fed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Day 1 and Day 20: Midazolam oral syrup: 2 mg, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Day 2 and Day 21: Digoxin tablet: 0.25 mg, fasted
Study: NCT05916885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: short-intensity modified CIMT and conventional therapy
Description: an experimental group receiving short-intensity modified CIMT and conventional therapy
Study: NCT04742894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Feedback Training
Description: Participants will be trained to work with a computer setup to control the position of a visual cursor on the screen using their speech while their auditory feedback is altered. The goal of the training is to help improve speech production and motor control ability.
Study: NCT05916885

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy alone
Description: a control group receiving conventional therapy alone.
Study: NCT04680897

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Early restriction release
Description: Participants will no longer have restrictions on vaginal penetration 2 weeks after surgery.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard restriction recommendation
Description: Participants will return to intercourse after 6 weeks
Study: NCT05507697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HUC-MSCs
Description: 5 × 10\^6 cells/mL, 1 mL per injection, each injection point is 2 cm apart ,1.0-1.5 cm deep, total amount of injection is estimated based on the surface area of the patient's lower limb

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Lipoic Acid
Description: Lipoic Acid Injection，600 mg/d for 15 consecutive days
Study: NCT05080595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transportation assistance (Lyft rides)
Description: Lyft rides will be provided to patients for any transplant-related medical visits
Study: NCT05448261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion-centered problem-solving intervention (EPi)
Description: The EPi is built upon the model of relational/problem-solving model of stress and is aimed at supporting caregivers in (1) revisiting stressful caregiving and associated problem from a psychological distanced perspective; (2) adopting problem orientation toward one's experience in the present moments with curiosity, openness and acceptance; and (3) applying the problem-solving skills learned for the enhancement of their psychosocial wellbeing in the stressful caregiving context. To reduce the incongruence between caregivers and stroke survivors in problem-solving, we will adopt a shared problem, shared action plan approach for the family caregivers and stroke survivors.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: stroke education
Description: Information is related to stroke and recurrent stroke and strategies for assisting stroke survivors in day-to-day activities.
Study: NCT05898763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)
Description: Patients will receive three rounds of vaccination three weeks apart via one subcutaneous (SC) injection in an alternating limb. Patients in the extension cohort will receive the highest safest dose in combination with pembrolizumab (a CPI).These patients will receive three rounds of combination treatment with TEIPP24 vaccination and pembrolizumab every three weeks. Pembrolizumab will be administered as per standard of care.
Study: NCT05425745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: 10 mg Obicetrapib tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet made to resemble active
Study: NCT06252207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: General anesthesia with desflurlane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: General anesthesia with isoflurane
Study: NCT05093140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Induction therapy:~Camrelizumab 200mg, ivd, D1, Rituximab 375mg/m2, ivd, D1 every 3 weeks up to 2 cycles~Immunochemotherapy:~Rituximab: 375mg/m2, ivd, D1; Cyclophosphamide: 750mg/m2, iv or ivd, D1; Hydroxyldaunorubicin: 50mg/m2, iv or ivd, D1; Vincristine: 1.4 mg/m2 , iv(max：2mg), D1; Prednisone: 60mg/m2, po, d1-5 every 3 weeks up to 6 cycles Maintenance therapy: Camrelizumab 200mg, ivd, D1 every 4 weeks up to 6 cycles
Study: NCT05143281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.4 MG [Dextenza]
Description: Ophthalmic Intracanalicular Insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.4 MG [Dextenza]
Description: Ophthalmic Intracanalicular Insert
Study: NCT05269433

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OCAT-sham
Description: Placebo version of the online contingent attention training preceded by a psycho-education movieclip.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OCAT
Description: Online contingent attention training preceded by a psycho-education movieclip.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OCAT
Description: Online contingent attention training preceded by a psycho-education movieclip.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psycho-education video
Description: All groups watch a psycho-education video before the start of the 10-day attention training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psycho-education video
Description: All groups watch a psycho-education video before the start of the 10-day attention training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education video
Description: All groups watch a psycho-education video before the start of the 10-day attention training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational video
Description: Participants in the OCAT+ condition watch a short motivational video before each training session.
Study: NCT05616975

Intervention type: OTHER
Intervention: test-retest reliability
Description: Assessing the test-retest reliability of SWAY Balance, Functional, and Cognitive tests.

Intervention type: OTHER
Intervention: construct validity
Description: Investigating the construct validity of SWAY Balance, Functional, and Cognitive tests.

Intervention type: OTHER
Intervention: normative data
Description: Collection of normative SWAY Balance, Functional, and Cognitive data.
Study: NCT05352711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active assisted exercise and with fully immersive Head-Mounted Display virtual reality ( Oculus Quest virtual reality (VR) headset with hand con
Description: VR is mainly created by generating visual effects through head-mounted display (HMD) systems. An HMD is a device worn on the head or as part of a helmet with a built-in display and lenses, allowing the user to experience the virtual world with the help of a wide viewing angle, head and hand movements tracking as well as objects interacting by controllers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active assisted range of motion exercise
Description: Patients were treated active assisted ROM physical therapy 2 sessions per week for 4 weeks.
Study: NCT05578170

Intervention type: DRUG
Intervention: Pembrolizumab
Description: Participants receive 200 mg pembrolizumab as a neoadjuvant by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles before surgery.
Study: NCT04239053

Intervention type: DRUG
Intervention: Bupivacaine
Description: Measuring the plasma concentration level of bupivacaine after applying ESPB
Study: NCT06550193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided procedure using AR/VR technology
Description: Participants will receive the intervention, which involves utilizing AR/VR technology during ultrasound-guided procedures (e.g., regional anesthesia, line placement). All participants will receive standard pre- and post-block or line care as they normally would for the ultrasound-guided procedure.
Study: NCT06232226

Intervention type: OTHER
Group type: OTHER
Intervention: Patients suffering from the co-occurrence of ADHD and addiction(s)
Description: All eligible patients over 15 years and 3 months (age limit between child psychiatry and adult psychiatry), presenting both a diagnosis of ADHD and a diagnosis of at least one addictive disorder (SUD, AUD (Alcohol Use Disorder) and/ or behavioral addiction), starting care in one of the three participating centers, and meeting the indication for treatment with MPH according to European recommendations (J. J. S. Kooij et al., 2019)
Study: NCT06219785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity Shockwave therapy (LiSWT)
Description: Participants will receive once-a-week LiSWT treatments of 0.2 mJ/ mm² over the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis once a week for six weeks, with a total of 6 treatments once a week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low-Intensity Shockwave therapy (LiSWT)
Description: Participants will receive once-a-week LiSWT treatments of 0.2 mJ/ mm² over the lateral penile shaft (distal, mid, and proximal penile shaft), 500 impulses in each area, for a total of 1500 shocks along the penis once a week for six weeks, with a total of 6 treatments once a week.
Study: NCT05356403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difelikefalin 1 mg Oral Tablet
Description: Difelikefalin 1 mg medication taken orally 1 time/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet taken orally 1 time/day
Study: NCT05612243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes and polyphenols
Description: Participants will consume a meal including 200g of yogurt enriched with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g) and polyphenol-rich lyophilized extract (250mg) of Cistus Albidus (77,3 mg GAE/g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of functional yogurt on postprandial glycemia and lipemia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes
Description: Participants will consume a meal including 200g of yogurt with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
Study: NCT04759144

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CamAPS FX using faster insulin aspart
Description: CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CamAPS FX using standard insulin aspart
Description: CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data
Study: NCT05612243

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Consumption of a meal with plain Yogurt with oat flakes
Description: Participants will consume a meal including 200g of plain yogurt containing 1g of oat flakes, as a placebo, as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
Study: NCT06281717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal Endotracheal Occlusion (FETO)
Description: The FETO insertion procedure will be performed between gestational age 27 weeks 0 days and 29 weeks and 6 days. The Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus using the Delivery Microcatheter (BALTACCI-BDPE100). The fetal tracheal balloon will be removed between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
Study: NCT06628596

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Paraxanthine 200mg and 300mg
Description: Participants consumed 200 mg paraxanthine (PXN 200), 300 mg paraxanthine (PXN 300), or placebo (PLA) after an overnight fast. Supplements were ingested 30 minutes before a mixed meal in double-blind, randomized, placebo-controlled, crossover fashion.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Paraxanthine 200mg and 300mg
Description: Participants consumed 200 mg paraxanthine (PXN 200), 300 mg paraxanthine (PXN 300), or placebo (PLA) after an overnight fast. Supplements were ingested 30 minutes before a mixed meal in double-blind, randomized, placebo-controlled, crossover fashion.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Paraxanthine 200mg and 300mg
Description: Participants consumed 200 mg paraxanthine (PXN 200), 300 mg paraxanthine (PXN 300), or placebo (PLA) after an overnight fast. Supplements were ingested 30 minutes before a mixed meal in double-blind, randomized, placebo-controlled, crossover fashion.
Study: NCT06630923

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human albumin
Description: Experimental intervention (Group A): Continuous slow IV infusion of Human Albumin, based on diuresis-adjusted dosing, not later than 30 minutes after randomisation and not later than 2 hours after admission. Concomitant continuous slow IV infusion of diuretics (furosemide) based on body weight- and diuresis-adjusted dosing. Control intervention (Group B): Continuous slow IV infusion of diuretics (furosemide), based on body weight - and diuresis-adjusted dosing. Experimental intervention (Human Albumin) is off-label treatment for patients with acute decompensation of CHF in Greece. Control intervention (IV diuretic therapy) is on-label treatment for acute decompensation CHF in Greece.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human albumin
Description: Experimental intervention (Group A): Continuous slow IV infusion of Human Albumin, based on diuresis-adjusted dosing, not later than 30 minutes after randomisation and not later than 2 hours after admission. Concomitant continuous slow IV infusion of diuretics (furosemide) based on body weight- and diuresis-adjusted dosing. Control intervention (Group B): Continuous slow IV infusion of diuretics (furosemide), based on body weight - and diuresis-adjusted dosing. Experimental intervention (Human Albumin) is off-label treatment for patients with acute decompensation of CHF in Greece. Control intervention (IV diuretic therapy) is on-label treatment for acute decompensation CHF in Greece.